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Background: Surgeon-level operative mortality is widely seen as a measure of quality after gastric and
oesophageal resection. This study aimed to evaluate this alongside a compound-level outcome analysis.
Methods: Consecutive patients who underwent treatment including surgery delivered by a multidisci-
plinary team, which included seven specialist surgeons, were studied. The primary outcome was death
within 30days of surgery; secondary outcomes were anastomotic leak, Clavien–Dindo morbidity score,
lymph node harvest, circumferential resection margin (CRM) status, disease-free (DFS), and overall (OS)
survival.
Results: The median number of annual resections per surgeon was 10 (range 5–25), compared with 14
(5–25) for joint consultant teams (P = 0⋅855). Themedian annual surgeon-level mortality rate was 0 (0–9)
per cent versus an overall network annual operative mortality rate of 1⋅8 (0–3⋅7) per cent. Joint consultant
team procedures were associated with fewer operative deaths (0⋅5 per cent versus 3⋅4 per cent at surgeon
level; P = 0⋅027). The median surgeon anastomotic leak rate was 12⋅4 (range 9–20) per cent (P = 0⋅625
versus the whole surgical range), overall morbidity 46⋅5 (31–60) per cent (P = 0⋅066), lymph node harvest
16 (9–29) (P< 0⋅001), CRM positivity 32⋅0 (16–46) per cent (P = 0⋅003), 5-year DFS rate 44⋅8 (29–60)
per cent and OS rate 46⋅5 (35–53) per cent. No designated metrics were independently associated with
DFS or OS in multivariable analysis.
Conclusion: Annual surgeon-level metrics demonstrated wide variations (fivefold), but these perfor-
mance metrics were not associated with survival.
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Introduction
There is considerable evidence that there is a relationship
between increasing volume and decreasing surgical mor-
tality following oesophagogastric resection for cancer. The
evidence is stronger for institutional outcomes than for
individual surgeons1–3. Specialist multidisciplinary team
(MDT) expertise has been reported to improve patient
outcomes4–6, but remains untested by a randomized trial.
Quality assurance metrics in surgery have traditionally
included operative mortality within 30 days of an opera-
tion. The UK National Oesophago-Gastric Cancer Audit
includes other variables as indicators of surgical quality
related to lymph node harvest, circumferential resection
margin (CRM) involvement and duration of hospital stay,
although not disease-free (DFS) or overall (OS) survival.
The aim of this study was to evaluate all of the compound
metrics of surgical quality assurance at surgeon and unit
level, using time frames of 1-, 3- and 5-year survival as
end-points.
Methods
The South EastWales CancerNetwork serves a population
of about 1⋅75 million. It involves ten acute, eight district
general and two teaching hospitals. Before August 2010,
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Table 1 Collective and individual surgeon-level postoperative outcome
Collective
(n = 525)
S1
(n = 64)
S2
(n = 92)
S3
(n = 112)
S4
(n = 90)
S5
(n = 54)
S6
(n = 38)
S7
(n = 75)
Age (years)
<65 222 (42⋅3) 23 (36) 40 (43) 57 (50⋅9) 30 (33) 26 (48) 13 (34) 33 (44)
65–75 217 (41⋅3) 21 (33) 36 (39) 41 (36⋅6) 42 (47) 23 (43) 21 (55) 33 (44)
>75 86 (16⋅4) 20 (31) 16 (17) 14 (12⋅5) 18 (20) 5 (9) 4 (11) 9 (12)
Sex
F 119 (22⋅7) 18 (28) 24 (26) 32 (28⋅6) 17 (19) 9 (17) 6 (16) 13 (17)
M 406 (77⋅3) 46 (72) 68 (74) 80 (71⋅4) 73 (81) 45 (83) 32 (84) 62 (83)
Neoadjuvant therapy†
None 197 (43⋅8) 23 (52) 33 (41) 49 (51) 44 (57) 20 (44) 7 (19) 21 (30)
Chemotherapy 200 (44⋅4) 16 (36) 39 (48) 38 (39) 26 (34) 18 (40) 23 (62) 40 (58)
Chemoradiotherapy 53 (11⋅8) 5 (11) 9 (11) 10 (10) 7 (9) 7 (16) 7 (19) 8 (12)
Tumour location
Oesophagus 311 (59⋅2) 33 (52) 55 (60) 69 (61⋅6) 44 (49) 34 (63) 26 (68) 50 (67)
Stomach 214 (40⋅8) 31 (48) 37 (40) 43 (38⋅4) 46 (51) 20 (37) 12 (32) 25 (33)
Operation type†
Transhiatal oesophagectomy 140 (31⋅1) 20 (45) 23 (28) 44 (45) 23 (30) 15 (33) 2 (5) 13 (19)
Ivor Lewis procedure 126 (28⋅0) 5 (11) 27 (33) 15 (15) 14 (18) 12 (27) 20 (54) 33 (48)
Total gastrectomy 96 (21⋅3) 6 (14) 17 (21) 16 (16) 21 (27) 10 (22) 10 (27) 16 (23)
Subtotal gastrectomy 88 (19⋅6) 13 (30) 14 (17) 22 (23) 19 (25) 8 (18) 5 (14) 7 (10)
Open and close
No 450 (85⋅7) 44 (69) 81 (88) 97 (86⋅6) 77 (86) 45 (83) 37 (97) 69 (92)
Yes 75 (14⋅3) 20 (31) 11 (12) 15 (13⋅4) 13 (14) 9 (17) 1 (3) 6 (8)
Margin status†
Negative 306 (68⋅0) 34 (77) 44 (54) 66 (68) 65 (84) 33 (73) 21 (57) 43 (62)
Positive 144 (32⋅0) 10 (23) 37 (46) 31 (32) 12 (16) 12 (27) 16 (43) 26 (38)
Lymph node yield* 16 (11–23) 15 (9–21) 17 (13–24) 14 (10–18) 14 (10–20) 11 (9–20) 13 (11–20) 24 (17–29)
Morbidity
No 280 (53⋅3) 44 (69) 49 (53) 61 (54⋅5) 49 (54) 27 (50) 20 (53) 30 (40)
Yes 245 (46⋅7) 20 (31) 43 (47) 51 (45⋅5) 41 (46) 27 (50) 18 (47) 45 (60)
Anastomotic leak†
No 394 (87⋅6) 40 (91) 71 (88) 87 (90) 69 (90) 36 (80) 33 (89) 58 (84)
Yes 56 (12⋅4) 4 (9) 10 (12) 10 (10) 8 (10) 9 (20) 4 (11) 11 (16)
Clavien–Dindo morbidity grade
0 255 (48⋅6) 42 (66) 42 (46) 57 (50⋅9) 43 (48) 24 (44) 19 (50) 28 (37)
I 25 (4⋅8) 2 (3) 7 (8) 4 (3⋅6) 6 (7) 3 (6) 1 (3) 2 (3)
II 147 (28⋅0) 14 (22) 24 (26) 29 (25⋅9) 25 (28) 13 (24) 9 (24) 33 (44)
III 61 (11⋅6) 4 (6) 13 (14) 13 (11⋅6) 9 (10) 9 (17) 3 (8) 10 (13)
IV 25 (4⋅8) 2 (3) 4 (4) 7 (6⋅3) 5 (6) 3 (6) 3 (8) 1 (1)
V 12 (2⋅3) 0 (0) 2 (2) 2 (1⋅8) 2 (2) 2 (4) 3 (8) 1 (1)
30-day mortality
No 513 (97⋅7) 64 (100) 90 (98) 110 (98⋅2) 88 (98) 52 (96) 35 (92) 74 (99)
Yes 12 (2⋅3) 0 (0) 2 (2) 2 (1⋅8) 2 (2) 2 (4) 3 (8) 1 (1)
Length of hospital stay (days)* 14 (11–20) 13 (11–15) 15 (12–21) 15 (12–21) 14 (12–23) 13 (11–18) 14 (11–18) 14 (12–18)
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.). †In the 450 patients who had a resection. S, surgeon.
eight surgeons undertook surgery at four different hospi-
tal sites, but since 2010 all resectional surgery has been
undertaken at a single site involving six specialist upper
gastrointestinal (UGI) surgeons carrying out all cancer
resectional surgery, three based at the surgical centre and
three operating on an in-reach basis, with a facility for joint
consultant operating. A seventh surgeon joined the team
in 2017.
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Table 2 Influence of dual consultant team operating strategy on
clinical outcomes
Team
operating
(n = 206)
Individual
operating
(n = 319) P‡
Age (years) 0⋅029
<65 98 (47⋅6) 124 (38⋅9)
65–75 81 (39⋅3) 136 (42⋅6)
>75 27 (13⋅1) 59 (18⋅5)
Sex 0⋅986
F 47 (22⋅8) 72 (22⋅6)
M 159 (77⋅2) 247 (77⋅4)
Neoadjuvant therapy 0⋅394
None 93 (45⋅1) 136 (42⋅6)
Chemotherapy 95 (46⋅1) 143 (44⋅8)
Chemoradiotherapy 18 (8⋅7) 40 (12⋅5)
Tumour location 0⋅712
Oesophagus 120 (58⋅3) 191 (59⋅9)
Stomach 86 (41⋅7) 128 (40⋅1)
Operation type† 0⋅505
Transhiatal oesophagectomy 63 (37⋅3) 77 (27⋅4)
Ivor Lewis procedure 36 (21⋅3) 90 (32⋅0)
Total gastrectomy 35 (20⋅7) 61 (21⋅7)
Subtotal gastrectomy 35 (20⋅7) 53 (18⋅9)
Open and close 0⋅053
No 169 (82⋅0) 281 (88⋅1)
Yes 37 (18⋅0) 38 (11⋅9)
Margin status† 0⋅205
Negative 121 (71⋅6) 185 (65⋅8)
Positive 48 (28⋅4) 96 (34⋅2)
Lymph node yield* † 14 (10–21) 16 (11–24) 0⋅012§
Morbidity† 0⋅807
No 82 (48⋅5) 133 (47⋅3)
Yes 87 (51⋅5) 148 (52⋅7)
Anastomotic leak† 0⋅993
No 148 (87⋅6) 246 (87⋅5)
Yes 21 (12⋅4) 35 (12⋅5)
Clavien–Dindo morbidity grade† 0⋅467
0 73 (43⋅2) 120 (42⋅7)
I 9 (5⋅3) 13 (4⋅6)
II 54 (32⋅0) 85 (30⋅2)
III 23 (13⋅6) 37 (13⋅2)
IV 9 (5⋅3) 15 (5⋅3)
V 1 (0⋅6) 11 (3⋅9)
30-day mortality 0⋅027
No 205 (99⋅5) 308 (96⋅6)
Yes 1 (0⋅5) 11 (3⋅4)
Length of hospital stay* 14 (12–20) 14 (11–20) 0⋅966§
Overall survival (%)
1-year 94⋅0 90⋅8
2-year 74⋅7 71⋅6
3-year 61⋅1 63⋅0
5-year 41⋅5 51⋅1
Values in parentheses are percentages unless indicated otherwise; *values
aremedian (range). †In the 450 patients who had a resection. ‡χ2 or Fisher’s
exact test, except §Mann–Whitney U test.
Diagnosis and staging was undertaken locally, coordi-
nated via three local weekly MDT meetings. All patients
deemed suitable for curative treatment were discussed at
a weekly regional network MDT meeting. Integral to the
new surgical model was the establishment of an enhanced
recovery programme7 based on established principles in
colorectal surgery8.
Data regarding the oesophageal and gastric cancer work-
load were collected using a combination of a prospectively
developed database in combination with MDT records
and review of hospital records. Pathological variables were
recorded from histopathology reports issued at the time of
surgery. CRMstatus was defined using theRoyal College of
Pathologists guidelines9,10. Measures of outcome included
postoperative morbidity and mortality, length of hospital
stay and survival at 1, 3 and 5 years from diagnosis. Patients
were followed up at regular intervals of 3months for the
first year and 6months thereafter. In the event that patients
developed symptoms suggestive of recurrent disease, inves-
tigations were undertaken sooner. Follow-up surveillance
was conducted for 5 years or until death, whichever was
sooner. Dates and causes of death were obtained from the
Wales Cancer Intelligence and Surveillance Unit and from
the Office for National Statistics. Regional ethical approval
was sought, but deemed unnecessary because the study was
considered to be service evaluation.
All patients had management plans individually tailored
according to factors relating to both patient and stage of
disease11. Staging included CT, endoscopic ultrasonog-
raphy, CT–PET and staging laparoscopy as appropri-
ate. The South East Wales MDT treatment algorithms
for oesophageal and gastric cancer have been described
previously12,13. Operative morbidity was graded in accor-
dance with the Clavien–Dindo classification14,15. Partic-
ular emphasis was placed on the incidence of morbid-
ity of grade III or higher. Definitive chemoradiotherapy
was offered to patients with localized squamous cell carci-
noma and to patients with adenocarcinoma deemed unsuit-
able for surgery because of disease extent and/or medical
co-morbidity16,17.
Statistical analysis
Grouped data were expressed as median (i.q.r.) values, and
non-parametric statistical methods were used. Continuous
data were compared using the Mann–Whitney U test,
and categorical data using the χ2 test or Fisher’s exact test
when the number of events was low. A non-parametric
two-sample test on the equality of medians was carried
out. Differences were deemed to be statistically significant
when the P value was less than 0⋅050.
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Table 3 Collective, 3-yearly and annual measurements of operative and perioperative metrics
Collective 3-yearly measures Yearly measures
2010–2018
(n = 525)
2010–2012
(n = 125)
2012–2015
(n = 177)
2015–2018
(n = 223)
2011
(n = 70)
2012
(n = 55)
2013
(n = 38)
2014
(n = 62)
2015
(n = 77)
2016
(n = 78)
2017
(n = 62)
2018
(n = 83)
Neoadjuvant therapy
None 197 (43⋅8) 62 (49⋅6) 71 (40⋅1) 96 (43⋅0) 30 (43) 32 (58) 15 (39) 31 (50) 25 (32) 34 (44) 26 (42) 36 (43)
Chemotherapy 200 (44⋅4) 62 (49⋅6) 76 (42⋅9) 100 (44⋅8) 39 (56) 23 (42) 19 (50) 22 (35) 35 (45) 34 (44) 31 (50) 35 (42)
Chemoradiotherapy 53 (11⋅8) 1 (0⋅8) 30 (16⋅9) 27 (12⋅1) 1 (1) 0 (0) 4 (11) 9 (15) 17 (22) 10 (13) 5 (8) 12 (14)
Operation type†
Transhiatal
oesophagectomy
140 (31⋅1) 33 (30⋅8) 59 (39⋅6) 48 (24⋅7) 14 (24) 19 (39) 14 (41) 21 (43) 24 (36) 11 (17) 14 (26) 23 (30)
Ivor Lewis procedure 126 (28⋅0) 22 (20⋅6) 27 (18⋅1) 77 (39⋅7) 14 (24) 8 (16) 4 (12) 8 (16) 15 (23) 28 (43) 18 (34) 31 (41)
Total gastrectomy 96 (21⋅3) 25 (23⋅4) 33 (22⋅1) 38 (19⋅6) 15 (26) 10 (20) 8 (24) 10 (20) 15 (23) 17 (26) 9 (17) 12 (16)
Subtotal gastrectomy 88 (19⋅6) 27 (25⋅2) 30 (20⋅1) 31 (16⋅0) 15 (26) 12 (24) 8 (24) 10 (20) 12 (18) 9 (14) 12 (23) 10 (13)
Open and close
No 450 (85⋅7) 107 (85⋅6) 149 (84⋅2) 194 (87⋅0) 58 (83) 49 (89) 34 (89) 49 (79) 66 (86) 65 (83) 53 (85) 76 (92)
Yes 75 (14⋅3) 18 (14⋅4) 28 (15⋅8) 29 (13⋅0) 12 (17) 6 (11) 4 (11) 13 (21) 11 (14) 13 (17) 9 (15) 7 (8)
Margin status†
Negative 306 (68⋅0) 70 (65⋅4) 101 (67⋅8) 135 (69⋅6) 36 (62) 34 (69) 22 (65) 35 (71) 44 (67) 46 (71) 40 (75) 49 (64)
Positive 144 (32⋅0) 37 (34⋅6) 48 (32⋅2) 59 (30⋅4) 22 (38) 15 (31) 12 (35) 14 (29) 22 (33) 19 (29) 13 (25) 27 (36)
Lymph node yield*† 16 (11–23) 16 (12–23) 12 (9–19) 17 (13–24) 17 (12–23) 15 (12–23) 12 (9–15) 11 (8–17) 14 (10–23) 14 (11–21) 17 (14–24) 20 (15–27)
Morbidity†
No 280 (53⋅3) 69 (55⋅2) 107 (60⋅5) 104 (46⋅6) 41 (59) 28 (51) 28 (74) 37 (60) 42 (55) 36 (46) 29 (47) 39 (47)
Yes 245 (46⋅7) 56 (44⋅8) 70 (39⋅5) 119 (53⋅4) 29 (41) 27 (49) 10 (26) 25 (40) 35 (45) 42 (54) 33 (53) 44 (53)
Anastomotic leak†
No 394 (87⋅6) 95 (88⋅8) 131 (87⋅9) 168 (86⋅6) 51 (88) 44 (90) 30 (88) 44 (90) 57 (86) 56 (86) 47 (89) 65 (86)
Yes 56 (12⋅4) 12 (11⋅2) 18 (12⋅1) 26 (13⋅4) 7 (12) 5 (10) 4 (12) 5 (10) 9 (14) 9 (14) 6 (11) 11 (14)
Clavien–Dindo morbidity
grade
0 255 (48⋅6) 66 (52⋅8) 90 (50⋅8) 99 (44⋅4) 38 (54) 28 (51) 18 (47) 34 (55) 38 (49) 35 (45) 26 (42) 38 (46)
I 25 (4⋅8) 3 (2⋅4) 17 (9⋅6) 5 (2⋅2) 3 (4) 0 (0) 10 (26) 3 (5) 4 (5) 1 | (1) 3 (5) 1 (1)
II 147 (28⋅0) 37 (29⋅6) 33 (18⋅6) 77 (34⋅5) 19 (27) 18 (33) 5 (13) 10 (16) 18 (24) 24 (31) 19 (31) 34 (41)
III 61 (11⋅6) 8 (6⋅4) 26 (14⋅7) 27 (12⋅1) 3 (4) 5 (9) 2 (5) 12 (19) 12 (16) 9 (12) 10 (16) 8 (10)
IV 25 (4⋅8) 9 (7⋅2) 8 (4⋅5) 8 (3⋅6) 5 (7) 4 (7) 1 (3) 3 (5) 4 (5.) 5 (6) 3 (5) 0 (0)
V 12 (2⋅3) 2 (1⋅6) 3 (1⋅7) 7 (3⋅1) 2 (3) 0 (0) 2 (5) 0 (0) 1 (1) 4 (5) 1 (2) 2 (2)
30-day mortality
No 513 (97⋅7) 123 (98⋅4) 174 (98⋅3) 216 (96⋅9) 68 (97) 55 (100) 36 (95) 62 (100) 76 (99) 74 (95) 61 (98) 81 (98)
Yes 12 (2⋅3) 2 (1⋅6) 3 (1⋅7) 7 (3⋅1) 2 (3) 0 (0) 2 (5) 0 (0) 1 (1) 4 (5) 1 (2) 2 (2)
Length of hospital stay
(days)*†
14 (11–20) 14 (11–19) 14 (11–20) 14 (12–20) 14 (11–20) 14 (11–18) 13 (12–17) 15 (13–23) 13 (11–19) 15 (13–25) 14 (12–23) 14 (11–16)
Survival (%)
1-year 92⋅1 92⋅5 89⋅3 94⋅0 91 94 82 92 91 92 94 98
2-year 72⋅9 74⋅8 69⋅8 75⋅8 81 67 56 69 77 69 89 n.a.
3-year 62⋅2 59⋅8 63⋅1 65⋅1 62 57 47 63 71 64 n.a. n.a.
5-year 46⋅5 47⋅8 47⋅7 44⋅4 50 45 35 55 n.a. n.a. n.a. n.a.
Values in parentheses are percentages unless indicated otherwise; *values are median (range). †In the 450 patients who had a resection. n.a., Not available.
DFS for all patients was calculated by measuring the
interval from a landmark time of 6months after diagno-
sis to the date of recurrence. This approach has been
adopted in previous randomized trials18, to allow for the
variable interval to surgery following diagnosis, depend-
ing onwhether neoadjuvant therapy was prescribed. Events
resulting in a failure to complete curative treatment, such
as not proceeding to surgery, open and close laparotomy,
palliative resection, in-hospital mortality and disease pro-
gression during neoadjuvant chemotherapy, were assumed
to have occurred at this landmark time, to maintain the
intention-to-treat analysis. Overall survival was measured
from the date of diagnosis. Cumulative survival was cal-
culated according to the Kaplan–Meier method; differ-
ences between groups were analysed with the log rank test.
Proportional hazard plots were created and Schoenfeld
residuals were calculated to confirm that the proportional
hazard assumption was appropriate for overall survival.
Univariable analyses involving potential factors influencing
survival were examined initially by the life-table method
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Table 4 Univariable and multivariable analysis of clinicopathological factors and complication markers, overall and disease-free
survival in the whole cohort
Overall survival Disease-free survival
Univariable analysis Multivariable analysis Univariable analysis Multivariable analysis
Hazard ratio P Hazard ratio P Hazard ratio P Hazard ratio P
Age (<65 versus 65–75
versus> 75 years)
1⋅16 (0⋅94, 1⋅43) 0⋅176 0⋅85 (0⋅66, 1⋅10) 0⋅210
Sex (F versus M) 0⋅95 (0⋅66, 1⋅36) 0⋅782 0⋅88 (0⋅59, 1⋅32) 0⋅531
Tumour site
(oesophageal versus
gastric)
1⋅03 (0⋅75, 1⋅41) 0⋅853 0⋅64 (0⋅44, 0⋅94) 0⋅023 0⋅34 (0⋅23, 0⋅52) < 0⋅001
Neoadjuvant therapy (no
versus yes)
1⋅25 (0⋅91, 1⋅72) 0⋅170 2⋅17 (1⋅47, 3⋅20) <0⋅001 0⋅162
Operation (THO versus
TTO versus TG versus
STG)
1⋅00 (0⋅88, 1⋅15) 0⋅952 0⋅85 (0⋅72, 0⋅99) 0⋅039 0⋅296
Individual surgeon
(S1–S8)
0⋅99 (0⋅93, 1⋅04) 0⋅620 1⋅02 (0⋅96, 1⋅08) 0⋅612
Team operating (no
versus yes)
0⋅96 (0⋅70, 1⋅32) 0⋅797 0⋅97 (0⋅68, 1⋅39) 0⋅875
Pathological factors
T category (T1 versus T2
versus T3 versus T4)
1⋅89 (1⋅60, 2⋅23) <0⋅001 1⋅66 (1⋅32, 2⋅07) <0⋅001 2⋅02 (1⋅66, 2⋅45) < 0⋅001 1⋅82 (1⋅42, 2⋅33) < 0⋅001
N category (N0 versus N1
versus N2 versus N3)
1⋅70 (1⋅49, 1⋅94) <0⋅001 1⋅34 (1⋅12, 1⋅60) 0⋅001 1⋅86 (1⋅59, 2⋅17) <0⋅001 1⋅59 (1⋅31, 1⋅94) < 0⋅001
TNM stage (I versus II
versus III versus IV)
2⋅10 (1⋅76, 2⋅50) <0⋅001 0⋅183 2⋅61 (2⋅10, 3⋅24) < 0⋅001 0⋅688
R status (R0 versus R1) 2⋅30 (1⋅68, 3⋅14) <0⋅001 0⋅330 2⋅63 (1⋅84, 3⋅76) <0⋅001 0⋅896
Postoperative factors
Postoperative morbidity
(no versus yes)
1⋅41 (1⋅03, 1⋅93) 0⋅030 0⋅40 (0⋅20, 0⋅80) 0⋅527 1⋅20 (0⋅84, 1⋅71) 0⋅319
Clavien–Dindo morbidity
grade
0 1⋅00 (reference) 1⋅00 (reference) 1⋅00 (reference)
I 1⋅17 (0⋅58, 2⋅36) 0⋅653 1⋅20 (0⋅59, 2⋅43) 0⋅619 1⋅13 (0⋅51, 2⋅49) 0⋅759
II 1⋅19 (0⋅81, 1⋅75) 0⋅382 1⋅52 (1⋅01, 2⋅29) 0⋅046 1,32 (0⋅88, 2⋅00) 0⋅182
III 1⋅26 (0⋅76, 2⋅08) 0⋅375 1⋅70 (1⋅02, 2⋅86) 0⋅044 0⋅95 (0⋅52, 1⋅75) 0⋅880
IV 1⋅67 (0⋅92, 2⋅02) 0⋅094 1⋅73 (0⋅94, 3⋅18) 0⋅077 1⋅31 (0⋅65, 2⋅65) 0⋅457
V 380 (113⋅84, 1268⋅53) <0⋅001 198⋅27 (58⋅92, 667⋅17) <0⋅001 0 (0⋅00, 4⋅00×10206) 0⋅968
Values in parentheses are 95 per cent confidence intervals. THO, transhiatal oesophagectomy; TTO, transthoracic oesophagectomy; TG, total gastrectomy;
STG, subtotal gastrectomy; S, surgeon.
of Kaplan and Meier, and those with associations where
P < 0⋅010 were retained in a Cox proportional hazards
model using forward conditional methodology to assess the
prognostic value of individual variables.
All statistical analysis was performed using IBM®SPSS®
statistics v25.0.0.0 (IBM, Armonk, New York, USA) with
extension R.
Results
In total, 525 patients were identified who underwent
surgery between August 2010 and August 2018 for
oesophagogastric cancer (oesophageal, 311; gastric, 214),
including 206 procedures (oesophageal cancer, 120 (58⋅3
per cent); gastric cancer, 86 (41⋅7 per cent)) performed
by two consultants working together. Sixteen patients had
laparoscopically assisted surgery during the study period
(oesophagectomy, 14 patients (5⋅3 per cent); gastrectomy,
2 (1⋅1 per cent)). The median annual resection number per
surgeon was 10 (range 5–25), compared with 14 (5–25)
for joint consultant teams (P = 0⋅855). The numbers of
surgical procedures performed by each surgeon (S) and as
a team (in parentheses) were: S1 64 (36), S2 92 (10), S3
112 (32), S4 90 (64), S5 54 (40), S6 38 (3) and S7 75 (21).
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Table 5 Univariable and multivariable analysis of clinicopathological factors and complication markers, overall and disease-free
survival in patients with oesophageal cancer
Overall survival Disease-free survival
Univariable analysis Multivariable analysis Univariable analysis Multivariable analysis
Hazard ratio P Hazard ratio P Hazard ratio P Hazard ratio P
Age (< 65 versus 65–75
versus>75 years)
1⋅10 (0⋅78, 1⋅55) 0⋅581 0⋅92 (0⋅63, 1⋅35) 0⋅668
Sex (F versus M) 1⋅13 (0⋅64, 2⋅00) 0⋅670 1⋅68 (0⋅84, 3⋅36) 0⋅142
Neoadjuvant therapy (no
versus yes)
1⋅62 (1⋅02, 2⋅57) 0⋅042 0⋅912 2⋅53 (1⋅46, 4⋅38) 0⋅001 0⋅362
Operation (THO versus TTO) 1⋅20 (0⋅84, 1⋅71) 0⋅309 1⋅02 (0⋅69, 1⋅50) 0⋅938
Individual surgeon (S1–S8) 0⋅99 (0⋅92, 1⋅06) 0⋅733 0⋅97 (0⋅90, 1⋅05) 0⋅454
Team operating (no versus
yes)
0⋅98 (0⋅65, 1⋅47) 0⋅914 1⋅12 (0⋅73, 1⋅74) 0⋅598
Pathological factors
T category (T1 versus T2
versus T3 versus T4)
2⋅17 (1⋅70, 2⋅77) <0⋅001 1⋅60 (1⋅21, 2⋅10) 0⋅001 2⋅15 (1⋅67, 2⋅78) <0⋅001 1⋅70 (1⋅27, 2⋅27) < 0⋅001
N category (N0 versus N1
versus N2 versus N3)
2⋅06 (1⋅72, 2⋅47) <0⋅001 1⋅66 (1⋅33, 2⋅07) <0⋅001 2⋅08 (1⋅69, 2⋅54) <0⋅001 1⋅61 (1⋅27, 2⋅05) < 0⋅001
TNM stage (I versus II versus
III versus IV)
2⋅35 (1⋅88, 2⋅94) <0⋅001 0⋅489 2⋅33 (1⋅84, 2⋅96) <0⋅001 0⋅607
R status (R0 versus R1) 3⋅31 (2⋅18, 5⋅02) <0⋅001 0⋅371 2⋅78 (1⋅79, 4⋅32) <0⋅001 0⋅792
Lymph node yield (< 15
versus≥15)
1⋅16 (0⋅77, 1⋅75) 0⋅484 0⋅96 (0⋅67, 1⋅38) 0⋅822
Postoperative factors
Postoperative morbidity (no
versus yes)
1⋅15 (0⋅76, 1⋅74) 0⋅499 1⋅04 (0⋅67, 1⋅61) 0⋅875
Clavien–Dindo morbidity
grade
0 1⋅00 (reference) 1⋅00 (reference)
I 1⋅00 (0⋅42, 2⋅36) 1⋅000 0⋅80 (0⋅28, 2⋅26) 0⋅797
II 1⋅00 (0⋅62, 1⋅62) 1⋅000 1⋅10 (0⋅66, 1⋅82) 0⋅725
III 1⋅00 (0⋅54, 1⋅85) 1⋅000 0⋅80 (0⋅39, 1⋅64) 0⋅546
IV 1⋅00 (0⋅46, 2⋅17) 1⋅000 1⋅07 (0⋅49, 2⋅34) 0⋅861
V 1⋅00 (0⋅00, 471⋅08) 1⋅000 0⋅00 (0⋅00, 127×10195) 0⋅966
Values in parentheses are 95 per cent confidence intervals. THO, transhiatal oesophagectomy; TTO, transthoracic oesophagectomy; S, surgeon.
The median age of patients undergoing resection was 66
(i.q.r. 59–72) years; some 42⋅3 per cent were aged less than
65 years. Most patients were men (77⋅3 per cent), and had
oesophageal cancer (59⋅2 per cent). For the whole cohort
of 525 patients, neoadjuvant therapy was offered to 296
patients (56⋅4 per cent) (chemotherapy, 238 (45⋅3 per cent);
chemoradiotherapy, 58 (11⋅0 per cent)). Some 244 patients
(46⋅5 per cent) developed postoperative complications, of
which 56 (12⋅4 per cent) were due to anastomotic leak.
There were 12 deaths (2⋅3 per cent) within 30 days of
surgery. The median length of hospital stay (LOS) for
patients having a resection was 14 (range 11–20) days
(Table 1).
During follow-up, 122 patients (23⋅2 per cent) developed
cancer recurrence, and 213 (40⋅6 per cent) died.
Unit versus individual surgeon data
Comparative data reported for unit and surgeon outcome
measures across the study period are shown in Table 1.
Transhiatal oesophagectomy was the commonest proce-
dure (140) (31⋅1 (range 5–45) per cent), followed by Ivor
Lewis oesophagectomy (126) (28⋅0 (11–54) per cent), total
gastrectomy (96) (21⋅3 (16–27) per cent) and subtotal gas-
trectomy (88) (19⋅6 (10–30) per cent). Open and close
laparotomy was performed in 75 patients (14⋅3 (range
3–31⋅3) per cent).
The CRM was positive in 144 patients (32⋅0 per cent)
(surgeon range 16–46 per cent) (P = 0⋅003 versus the
whole surgical range) and median lymph node yield was
16 (i.q.r. 11–23) (surgeon range 11 (i.q.r. 9–20) to 24
(17–29)) (P< 0⋅001). Postoperative morbidity occurred in
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Table 6 Univariable and multivariable analysis of clinicopathological factors and complication markers, overall and disease-free
survival in patients with gastric cancer
Overall survival Disease free survival
Univariable analysis Multivariable analysis Univariable analysis Multivariable analysis
Hazard ratio P Hazard ratio P Hazard ratio P Hazard ratio P
Age<65 versus 65–75
versus>75 years)
1⋅22 (0⋅90, 1⋅66) 0⋅205 0⋅94 (0⋅64, 1⋅39) 0⋅764
Sex (F versus M) 0⋅82 (0⋅50, 1⋅36) 0⋅446 0⋅35 (0⋅19, 0⋅66) 0⋅001 0⋅40 (0⋅21, 0⋅76) 0⋅005
Neoadjuvant therapy (no
versus yes)
1⋅01 (0⋅61,1⋅67) 0⋅966 1⋅51 (0⋅81, 2⋅81) 0⋅194
Operation (TG versus STG) 0⋅74 (0⋅49,1⋅11) 0⋅148 0⋅90 (0⋅53, 1⋅53) 0⋅700
Individual surgeon (S1–S8) 0⋅99 (0⋅90,1⋅08) 0⋅794 1⋅09 (1⋅00, 1⋅20) 0⋅064 0⋅085
Team operating (no versus
yes)
0⋅91 (0⋅55,1⋅49) 0⋅699 0⋅71 (0⋅37, 1⋅36) 0⋅304
Pathological factors
T category (T1 versus T2
versus T3 versus T4)
1⋅77 (1⋅37, 2⋅30) <0⋅001 1⋅81 (1⋅38, 2⋅37) <0⋅001 2⋅81 (1⋅84, 4⋅29) <0⋅001 2⋅12 (1⋅30, 3⋅47) < 0⋅001
N category (N0 versus N1
versus N2 versus N3)
1⋅44 (1⋅17, 1⋅77) 0⋅001 0⋅768 2⋅14 (1⋅60, 2⋅87) <0⋅001 1⋅44 (1⋅01, 2⋅05) 0⋅043
TNM stage (I versus II versus
III versus IV)
1⋅76 (1⋅31, 2⋅36) <0⋅001 0⋅484 3⋅41 (2⋅11, 5⋅51) <0⋅001 0⋅866
R status (0 versus 1) 1⋅36 (0⋅78, 2⋅40) 0⋅282 1⋅96 (0⋅99, 3⋅85) 0⋅052 0⋅658
Lymph node yield (< 15
versus≥15)
0⋅82 (0⋅50, 1⋅34) 0⋅420 1⋅09 (0⋅57, 2⋅08) 0⋅803
Postoperative factors
Postoperative morbidity (no
versus yes)
2⋅03 (1⋅24, 3⋅30) 0⋅005 0⋅28 (0⋅09, 0⋅89) 0⋅032 1⋅18 (0⋅62, 2⋅27) 0⋅612
Clavien–Dindo morbidity
grade
0 1⋅00 (reference) 1⋅00 (reference)
I 1⋅00 (0⋅32, 3⋅14) 1⋅000 1⋅70 (0⋅50, 5⋅57) 0⋅404
II 1⋅00 (0⋅54, 1⋅85) 1⋅000 1⋅38 (0⋅66, 2⋅89) 0⋅399
III 1⋅00 (0⋅40, 2⋅51) 1⋅000 0⋅96 (0⋅29, 3⋅20) 0⋅943
IV 1⋅00 (0⋅20, 5⋅00) 1⋅000 1⋅15 (0⋅16, 8⋅56) 0⋅888
V 1⋅00 (0⋅00, 566⋅54) 1⋅000 0⋅00 (0⋅00, 859×10300) 0⋅982
Values in parentheses are 95 per cent confidence intervals. TG, total gastrectomy; STG, subtotal gastrectomy; S, surgeon.
245 patients (46⋅7 (range 31–60) per cent) (P = 0⋅066).
Anastomotic leak occurred in 56 patients (12⋅4 (range
9–20) per cent) (P = 0⋅625). Major postoperative morbid-
ity (grade III or above) was observed in 98 patients (18⋅7
(range 9–26) per cent) and median LOS was 14 (i.q.r.
11–20) days, similar for all surgeons. The operative 30-day
mortality rate was 2⋅3 per cent (surgeon range 0–8 per
cent).
The 1-, 3- and 5-year survival rates at unit and individ-
ual level are shown in Table S1 (supporting information).
For oesophageal cancer, 1-, 3- and 5-year OS rates were
93⋅7 (range 86–100), 62⋅5 (54–71) and 44⋅6 (36–52) per
cent respectively, with 1-, 3- and 5-year DFS rates of 79⋅3
(69–91), 50⋅0 (20–59) and 37⋅2 (25–56) per cent respec-
tively. For gastric cancer, the 1-, 3- and 5-year OS rates
were 89⋅6 (73–100), 61⋅8 (42–100) and 48⋅7 (33–56⋅5) per
cent respectively, with 1-, 3- and 5-year DFS rates of 88⋅4
(69–100), 62⋅8 (40–80) and 57⋅4 (33–71) per cent respec-
tively.
Outcome parameters for consultant team approach
Baseline characteristics for patients grouped into individual
consultant and dual team consultant operating are shown
in Table 2. Dual consultant operating was performed in
206 procedures (39⋅2 per cent). Patients were younger in
the dual consultant operator cohort compared with those
in the individual consultant operator cohort (age below
65 years: 47⋅6 versus 38⋅9 per cent respectively; P = 0⋅029).
Proportions were similar with regard to sex (22⋅8 versus
22⋅6 per cent; P = 0⋅986), neoadjuvant chemotherapy (46⋅1
versus 44⋅8 per cent; P = 0⋅394) and tumour location (58⋅3
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Fig. 1 Kaplan–Meier analysis of overall and disease-free survival, stratified by individual surgeon
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versus 59⋅9 per cent; P = 0⋅712). Open and close opera-
tions were performed more commonly by dual consultant
teams (18⋅0 per cent versus 11⋅9 for individual surgeons;
P = 0⋅053), with lower lymph node harvests (median 14
versus 16 respectively; P = 0⋅012) and a lower operative
mortality rate within 30 days of surgery (0⋅5 versus 3⋅4
per cent; P = 0⋅027). CRM positivity (28⋅4 versus 34⋅2
per cent; P = 0⋅205), postoperative morbidity (51⋅5 versus
52⋅7 per cent; P = 0⋅807), anastomotic leak (12⋅4 versus
12⋅5 per cent; P = 0⋅993) and grade 0 morbidity (43⋅2
versus 42⋅7 per cent; P = 0⋅467) were similar irrespective
of operative team.
Collective, annual and 3-year measures of surgical
quality assurance
Complete characteristics related to quality assurance and
outcome measures are shown in Table 3. Comparison of
annual metrics in 2011 and 2018 revealed that in the latter
year more patients received chemoradiotherapy (1 per cent
in 2011 versus 14 per cent in 2018), more had an Ivor Lewis
oesophagectomy (24 versus 41 per cent respectively) and
fewer patients had an open and close procedure (17 versus 8
per cent). Other notable variations were found in the rates
of open and close procedures (21 per cent in 2014 versus 8
per cent in 2018), lymph node yield (11 (i.q.r. 8–17) in 2014
versus 20 (15–27) in 2018), postoperative morbidity (26 per
cent in 2013 versus 54 per cent in 2016), operative mortality
(0 per cent in 2012 and 2014 versus 5 per cent in 2016) and
5-year OS (55 per cent in 2014 versus 35 per cent in 2013)
(Table 3). The median annual surgeon-level mortality rate
was 0 (0–9) per cent versus an overall network annual rate
of 1⋅8 (0–3⋅7) per cent.
In contrast, when 3-year time frames were examined,
other than the prescription of neoadjuvant chemoradio-
therapy (0⋅8 per cent in 2010–2012 versus 16⋅9 per cent in
2012–2015) and the proportion of patients having an Ivor
Lewis oesophagectomy (18⋅1 per cent in 2012–2015 versus
39⋅7 per cent in 2015–2018), all other performancemetrics
were similar (Table 3).
Survival analysis
Univariable and multivariable survival analyses relating
to all patients are shown in Tables 4–6. There was no
relationship between OS or DFS and operating surgeon
(Fig. 1).
Discussion
This study examined compound-level clinical outcome
metrics across an UGI cancer network. The principal
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finding was that surgeon-level annual data varied markedly.
Operative mortality varied fivefold, anastomotic leak and
overall morbidity twofold, lymph node harvest threefold
and CRM positivity threefold. These annual variations
resulted in a 5-year cumulativeOS rate that varied by nearly
50 per cent, and a 5-year DFS rate that varied by about
30 per cent. Three-year outcome measures demonstrated
less variation than yearly measures and may be a superior
reporting metric for surgical performance.
A consultant team-focused operative approach to patients
with a high-risk profile was sevenfold safer in terms of
operative mortality within 30 days. Over a 3-year period,
the operative mortality rate varied by 1⋅5 per cent, anasto-
motic leak by 2⋅2 per cent, overall morbidity by 13⋅9 per
cent, lymph node harvest by 29 per cent, CRM positiv-
ity by 4⋅2 per cent, and 5-year cumulative OS by 3⋅4 per
cent. The hypothesis that there was no significant inter-
surgeon variation related to operative mortality was sup-
ported. Three-year time frames provided a more balanced
and uniform measure of performance than annual snap-
shots.
Clinical performance and patient outcome measures can
be used to improve patient safety and clinical effective-
ness. Public reporting of these metrics, such as individual
surgeon outcome data, is designed to demonstrate trans-
parency to consumers, allowing comparison and a sense of
competition. For those involved in the organization and
delivery of healthcare, these metrics can be used to set
performance targets that may be associated with financial
rewards or penalties at local, regional or national level.
In the context of UGI cancer surgery, operative mor-
tality has been the outcome measure made publicly avail-
able in the UK3. The publication of mortality data as an
indicator of quality of clinical care, however, may make
some surgeons reluctant to operate on high-risk patients19.
Because surgical mortality rates are extremely low (about
2 per cent), one extra death has a notable impact on a sur-
geon’s performance in a year, and risk-adjustment methods
cannot resolve such problems. The findings of this study
suggest that 3-yearly measures of quality including opera-
tive (margin status and lymph node yield) and postoperative
information (Clavien–Dindo grade above II and postoper-
ative death), together with 5-year OS and DFS rates are
necessary to measure surgical performance and outcome
objectively.
Other UK centres have reported their experience after
centralizing oesophagogastric cancer surgery20–22. In
terms of compound-level metrics, the reported rates for
anastomotic leak were 7⋅3 per cent20 to 10⋅0 per cent21,
margin involvement 46⋅0 per cent20, LOS 14 days20 and
postoperative mortality between 0 and 3⋅6 per cent20–22.
These figures are similar to those reported here and
support the notion that higher patient volumes result in
improved outcomes23. The centralization effect may in
part reflect technical performance of the surgeon, but also
includes performance of all team members contributing
to perioperative care, the recognition and management
of complications, and longer-term nutritional support
following discharge. Collectively, these features suggest
that institutional data may be more useful to healthcare
planners than those relating to individual surgeons.
This study has a number of limitations. Data were
obtained from a single UK regional cancer network, so it
is unclear to what extent the conclusions may apply else-
where. Relatively few patients underwent a minimally inva-
sive approach for either oesophageal or gastric cancer, as
this was introduced in 2017. Conversely, data were col-
lected in a contemporaneous way at all local and regional
MDT meetings over a period of over 8 years; survival data
were particularly robust because no patients were lost to
follow-up and death certification was obtained from the
Office for National Statistics.
Improvements in any arena demand the measurement
of results. Teams and their performance advance by trac-
ing progress over time and relating performance to rivals
both inside and outside their group. Rigorous value mea-
surements (clinical outcomes and costs) are vital steps in
refining healthcare. In the current arena of UGI cancer,
where operative mortality is now low, this measure alone
is no longer a robust predictor of long-term survival nor
a reliable measure of surgical performance when examined
on an annual basis.
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